1
Ductal Adenocarcinoma Case Study
MSN Nursing, St Thomas University
NUR 502: Advanced Pathophysiology
January 16, 2025
Ductal Adenocarcinoma Case Study
, Pancreatic Cancer Case Study 2
Potential Most Common Sites for Metastasis and Rationale
Pancreatic ductal adenocarcinoma (PDAC), as identified in J.C., is a highly aggressive
cancer known for its tendency to metastasize. The liver, lungs, peritoneum, and nearby lymph
nodes are the most frequent sites of metastasis (Montemagno et al., 2021). This occurs due to
the anatomical and vascular features of the pancreas. The liver often suffers because the
pancreatic venous drainage flows into the portal circulation, creating a direct route for tumor
cells.
Moreover, the lymphatic spread to the nearby nodes is common, thanks to the extensive
lymphatic system surrounding the pancreas. The lungs and peritoneum often become involved
because of dissemination through the bloodstream and throughout the body cavity respectively.
Tumor Cell Markers and Their Role in Pancreatic Cancer
Tumor cell markers are special molecules that come from cancer cells or are created by the
tumor in the body. They play a vital role in diagnosing, monitoring, and understanding
pancreatic cancer better. When it comes to pancreatic ductal adenocarcinoma (PDAC), two
common tumor markers are carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen
(CEA) (Tempero et al., 2022). CA 19-9 is particularly important since it’s elevated in about 70-
90% of PDAC cases, helping to relate to tumor size and how the disease progresses. These
markers are ordered to assist in diagnosis when imaging and clinical findings are unclear. They
help observe treatment responses and identify early recurrences. They also provide prognostic
information, as higher levels often indicate advanced disease.
TNM Stage Classification of J.C.'s Tumor
Ductal Adenocarcinoma Case Study
MSN Nursing, St Thomas University
NUR 502: Advanced Pathophysiology
January 16, 2025
Ductal Adenocarcinoma Case Study
, Pancreatic Cancer Case Study 2
Potential Most Common Sites for Metastasis and Rationale
Pancreatic ductal adenocarcinoma (PDAC), as identified in J.C., is a highly aggressive
cancer known for its tendency to metastasize. The liver, lungs, peritoneum, and nearby lymph
nodes are the most frequent sites of metastasis (Montemagno et al., 2021). This occurs due to
the anatomical and vascular features of the pancreas. The liver often suffers because the
pancreatic venous drainage flows into the portal circulation, creating a direct route for tumor
cells.
Moreover, the lymphatic spread to the nearby nodes is common, thanks to the extensive
lymphatic system surrounding the pancreas. The lungs and peritoneum often become involved
because of dissemination through the bloodstream and throughout the body cavity respectively.
Tumor Cell Markers and Their Role in Pancreatic Cancer
Tumor cell markers are special molecules that come from cancer cells or are created by the
tumor in the body. They play a vital role in diagnosing, monitoring, and understanding
pancreatic cancer better. When it comes to pancreatic ductal adenocarcinoma (PDAC), two
common tumor markers are carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen
(CEA) (Tempero et al., 2022). CA 19-9 is particularly important since it’s elevated in about 70-
90% of PDAC cases, helping to relate to tumor size and how the disease progresses. These
markers are ordered to assist in diagnosis when imaging and clinical findings are unclear. They
help observe treatment responses and identify early recurrences. They also provide prognostic
information, as higher levels often indicate advanced disease.
TNM Stage Classification of J.C.'s Tumor
